Key Takeaways:
- Barron's recommends Verizon, Clorox, Pfizer and Comcast as dividend buys
- The four stocks offer yields ranging from 3.2% to 6.5%
- Dividend stocks are flashing a buy signal amid favorable market conditions
Key Takeaways:

Barron's recommended four dividend-paying stocks — Verizon Communications Inc., Clorox Co., Pfizer Inc. and Comcast Corp. — as a buy signal for income investors, citing favorable conditions for dividend investing.
"Dividend stocks are offering compelling entry points as the market rotates toward value," the publication said in its July 10 report. "These companies have the cash flow to sustain and grow their payouts."
Verizon yields about 6.5%, the highest among the group, supported by its telecom infrastructure cash flows. Clorox offers a 3.2% yield backed by consumer staples demand that has held steady through economic cycles. Pfizer's dividend sits near 5.7%, anchored by its diversified drug portfolio, while Comcast pays roughly 3.5% from its media and broadband operations.
The recommendation comes as the S&P 500 trades near 7,582, with the 10-year Treasury yield above 4.5%. Dividend stocks have underperformed growth names for much of the past two years, but the Barron's report argues that the gap is narrowing as the rate environment stabilizes and investors seek income alternatives to bonds.
For income investors, the four picks span defensive and cyclical sectors, reducing single-industry risk. Verizon and Clorox provide recession-resistant cash flows, while Pfizer offers pharmaceutical pricing power and Comcast benefits from broadband subscription revenue. The average yield across the group is roughly 4.7%, compared with about 1.3% for the S&P 500.
The next catalyst for these stocks will be second-quarter earnings reports starting later this month. Investors will watch Verizon's wireless subscriber additions, Clorox's gross margin trajectory, Pfizer's pipeline updates and Comcast's broadband net adds as signals of dividend sustainability.
This article is for informational purposes only and does not constitute investment advice.